|
Supplementary Protection Certificate (SPC) Summary of Applications |
|||
| SPC No. | 2016/036 | ||
|---|---|---|---|
| Date of filing | 23/08/2016 | ||
| Notification of Application Published | 21/09/2016 | ||
| Status | Withdrawn | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
AMGEN INC. One Amgen Center Drive Thousand Oaks CA 91320-1799 UNITED STATES OF AMERICA |
||
| Patent Number | 2215124 | ||
| Title of Invention | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | ||
| Date of Expiry of Patent | 21/08/2028 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Alirocumab | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/15/1031/001 TO EU/1/15/1031/012 | ||
| Authorisation Date | 23/09/2015 | ||
| Identity of Product Authorised | Praluent - alirocumab | ||
| Address for Service |
Anne Ryan & Co 2 Crofton Terrace Dun Laoghaire Co. Dublin A96 V6P7 IRELAND |
||
| Renewal Fees | |||
| 24/08/2016 | Request for grant a Supplementary Protection Certificate filed on 23/08/2016, numbered 2016/036. | ||
| 16/11/2020 | Request for grant of Supplementary Protection Certificate No. 2016/036 withdrawn on 16/11/2020. | ||